Ocata leverages proprietary pluripotent stem cell platforms (human embryonic stem cells and induced pluripotent stem cells) to address significant unmet medical needs in ophthalmology. Following its acquisition by Astellas in (February 2016) for $379 million, the company operates as Astellas' regenerative ophthalmology innovation center with clinical-stage pipeline programs.
Cyborg Score Rationale
As a subsidiary of a major pharmaceutical company with established clinical programs and strong IP protections, Ocata has solid fundamentals but limited independence metrics. The regenerative medicine space is competitive with multiple players pursuing similar stem cell therapies.
Top Insights
Core focus on regenerative ophthalmology with multiple programs in clinical development for serious macular degeneration conditions
Strong intellectual property portfolio protecting pluripotent stem cell platforms across multiple formats and formulations
Part of Astellas Pharma—providing financial stability and global distribution capabilities for future approvals
Founded in 1994 as Advanced Cell Technology with deep roots in stem cell research and biomedical innovation
Named Competitors
Regenerative Medicine Advanced Therapies — Cell and gene therapy approaches for ophthalmology
Cell Therapy Programs — Regenerative medicine and cell-based treatments
Recent Developments
(February 2016) Acquired by Astellas Pharma for $379 million
Open the full interactive Ocata Therapeutics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.